ABSTRACT
In this study 14 women suffering from symptomatic bacterial vaginosis were treated with tetridamine at a dose of 2 lavages/day for 7 days. The results obtained confirmed the value of tetridamine on account of the high percentage of recovery, the rapid diminution in the degree of bacterial infection and the excellent tolerability of the product.
Subject(s)
Bacterial Infections/microbiology , Indazoles/administration & dosage , Vaginitis/microbiology , Vulvovaginitis/microbiology , Administration, Topical , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Bacterial Infections/drug therapy , Female , Humans , Therapeutic Irrigation , Vaginitis/drug therapy , Vulvovaginitis/drug therapyABSTRACT
The therapeutic efficacy and tolerability of the antifungal agent ciclopiroxolamine have been verified with a double-blind study versus clotrimazole in 46 patients affected by vulvovaginal candidiasis. The patients of the first group (23) have been treated with ciclopiroxolamine globules, one 100 mg globule nightly for six days; the second group (23 patients) received clotrimazole vaginal tablets, one 200 mg tablet nightly for six days. Ciclopiroxolamine treatment showed an equivalent effectiveness to that of clotrimazole both on signs and symptoms and on vaginal smear culture. No local or systemic adverse reaction was observed.
Subject(s)
Antifungal Agents/therapeutic use , Candidiasis, Vulvovaginal/drug therapy , Clotrimazole/therapeutic use , Imidazoles/therapeutic use , Pyridones/therapeutic use , Administration, Intravaginal , Adolescent , Adult , Aged , Antifungal Agents/adverse effects , Ciclopirox , Clotrimazole/adverse effects , Double-Blind Method , Drug Tolerance , Female , Humans , Middle Aged , Pyridones/adverse effects , Randomized Controlled Trials as Topic , TabletsABSTRACT
We have verified the local activity and tolerance of the antimycotic drug ciclopiroxolamine in an open trial. The study included 34 women suffering from clinically and mycologically diagnosed vulvovaginitis caused by Candida. The therapy consisted of inserting a 100 mg ovule of ciclopiroxolamine once a day for 3 days. The cultural examination was negative in 76.5% of cases at the 1st control after the treatment and in 82.3% of cases at the 2nd control after the treatment. All the considered subjective and objective symptoms showed a highly significant decrease of frequency and intensity. No chemical parameter was modified; only in one patient a very mild side effect was verified.
